Implementation Checklist
The preceding sections describe what to do; this section specifies when to do it. The checklist that follows translates the multi-domain protocols into a sequenced, time-stamped action plan that a patient, caregiver, or physician can execute without further interpretation. It is organised in three escalating timescales that align with the chapter’s overall trajectory from crisis to stabilisation to recovery.
Week 1 targets the highest-urgency symptom domains with interventions that can be initiated on the same day—antihistamines, salt and fluid loading, compression garments, sleep support, and pacing. Weeks 2–4 consolidate gains, troubleshoot insufficient responses, and begin planning medium-term interventions including comprehensive biomarker testing and identification of physicians willing to prescribe off-label therapies. Months 2–6 move into medium-term territory: immunoadsorption for patients with autoantibody-positive cognitive dysfunction, trials of low-dose IL-2 or hormonal modulation where indicated, and continued optimisation of the foundational immediate protocols. Each checkbox corresponds to an action already justified in the preceding substantive sections; the checklist structure is designed to reduce the executive-function burden on patients and caregivers who are already operating at their cognitive limit.
1 Week 1: Immediate Action
Day 1 (TODAY):
- \(square.stroked\): Purchase: H1 antihistamine (cetirizine), H2 antihistamine (famotidine)
- \(square.stroked\): Begin strict low-histamine diet
- \(square.stroked\): Order compression garments (overnight shipping)
- \(square.stroked\): Begin salt loading (6 g/day) + fluids (3 L/day)
- \(square.stroked\): Purchase: Melatonin, magnesium glycinate (for sleep tonight)
- \(square.stroked\): Obtain heart rate monitor
- \(square.stroked\): Begin strict pacing (stay below anaerobic threshold)
- \(square.stroked\): Start pain management (ibuprofen or naproxen + topicals if available)
- \(square.stroked\): Call physician: Request trazodone or mirtazapine for sleep (prefer trazodone 25-50 mg as it enhances SWS without suppressing NE oscillations that drive glymphatic clearance; SleepFM demonstrates that cross-modal decoupling during sleep predicts disease onset across 130+ conditions (Thapa et al. 2026), providing indirect support for coupling-preserving sleep aids, though no interventional data exist)
Days 2–3:
- \(square.stroked\): Compression garments arrive → wear before rising from bed
- \(square.stroked\): Add GI support: Ondansetron for nausea (request prescription), loperamide PRN
- \(square.stroked\): Add cognitive support: Alpha-GPC, L-tyrosine, caffeine+theanine
- \(square.stroked\): Evaluate MCAS response: If 30–50% improvement → continue; add quercetin 500 mg BID
Days 4–7:
- \(square.stroked\): If MCAS helping → request cromolyn sodium prescription
- \(square.stroked\): If sleep poor → refine pharmaceutical approach (titrate dose, try alternatives)
- \(square.stroked\): If pain severe → request gabapentin or low-dose naltrexone
- \(square.stroked\): If dysautonomia severe → request fludrocortisone
- \(square.stroked\): Add gut barrier support: L-glutamine, zinc carnosine
- \(square.stroked\): Assess overall response: Which protocols helping most? Prioritize and optimize.
2 Weeks 2–4: Consolidation and Planning
- \(square.stroked\): Assess 2-week outcomes (Table Expected 2-Week Outcomes)
- \(square.stroked\): If suffering reduced to bearable level → maintain protocols, begin medium-term planning
- \(square.stroked\): If insufficient improvement → troubleshoot (which protocols not working? Try alternatives)
- \(square.stroked\): Schedule comprehensive biomarker testing (cytokines, immune subsets, autoantibodies)
- \(square.stroked\): Research immunoadsorption centers if severe cognitive dysfunction
- \(square.stroked\): Identify physician willing to prescribe off-label therapies (low-dose IL-2, anti-cytokines)
- \(square.stroked\): If post-menopausal woman → check estradiol levels
3 Months 2–6: Medium-Term Interventions
- \(square.stroked\): Pursue immunoadsorption if indicated (cognitive dysfunction + autoantibodies)
- \(square.stroked\): Trial low-dose IL-2 if Treg deficiency + autoimmune features
- \(square.stroked\): Trial estrogen if post-menopausal + low estradiol + high IL-6
- \(square.stroked\): If early disease (\(<\) 3 years) + high cytokines → discuss anti-cytokine biologics
- \(square.stroked\): Continue all effective immediate protocols (pacing, MCAS, sleep, etc.)
- \(square.stroked\): Reassess every 4–6 weeks: What’s working? What needs adjustment?
3.1 Wheat Elimination Trial for Severe/Bedbound Patients
Baseline gut barrier dysfunction (elevated zonulin, LPS, sCD14 in ME/CFS populations (Martín-Núñez et al. 2023)) combined with chronic low-grade splanchnic hypoperfusion from dysautonomia Wijck et al. (2011) creates sustained intestinal ischemic stress in bedbound patients. Wheat consumption upregulates zonulin via gliadin and \(\alpha\)-amylase trypsin inhibitors (Junker et al. 2012), potentially perpetuating tight junction sensitization. Wheat elimination may benefit bedbound patients by reducing baseline gut permeability independent of activity triggers, producing gradual improvements in symptom “noise floor” and quality of life that are inaccessible to patients who cannot exercise.
Certainty: 0.60 (gut permeability dysfunction documented in ME/CFS (Martín-Núñez et al. 2023); gliadin-zonulin mechanism established (Junker et al. 2012); splanchnic hypoperfusion in dysautonomia documented Wijck et al. (2011); direct evidence for wheat elimination efficacy in severe/bedbound ME/CFS patients is lacking; extrapolates from ambulatory wheat-exercise intolerance data; untested specifically in bedbound populations)
Implementation for Severe Patients:
Pre-trial screening: Assess nutritional status (serum albumin, CBC); severe malnutrition or active eating disorders are contraindications. Confirm caregiver availability for meal preparation during trial.
Trial structure: 12–16 week full wheat elimination (strict: no gliadin-containing foods). Unlike ambulatory patients who may see acute post-exercise benefit, expect gradual baseline changes over weeks 6–12.
Expected outcomes: Reduced brain fog, pain, and symptom severity; improved orthostatic tolerance if dysautonomia-linked; gradual energy floor improvement within severe limitations; NOT expected: rapid breakthrough improvements or PEM prevention (since patient does not exercise).
Monitoring: Weekly subjective tracking (fatigue, cognitive clarity, baseline pain) and objective markers if available (LPS, zonulin, I-FABP measured at weeks 0, 6, 12 if affordable). Symptom changes develop slowly—patience essential.
Safety requirements: Monitor for nutritional deficiency (fatigue, anemia progression, hair loss); if deficiency emerges, add supplemental protein (shakes, amino acids). Ensure adequate caloric intake (wheat removal may reduce calories; add alternative carbohydrate sources). Screen for eating disorder risk (some severe patients may have coexisting ED).
Success definition: If 20–30% improvement in baseline symptom severity by week 12, consider permanent elimination. If no improvement, reintroduce wheat by week 16 and explore other barriers (FODMAPs, histamine, other food sensitivities).